Zydus Drops 4.6% as US Revlimid Exclusivity Ends — Is India’s Biosimilar Bet Losing Its Biggest Revenue Catalyst?

Mon Apr 13 2026

Zydus Lifesciences — India’s fifth-largest pharma company and the beneficiary of the US FDA’s most valuable recent generic exclusivity (Revlimid) — dropped 4.6% as Revlimid (lenalidomide) authorised generic revenue began its inevitable decline as the 180-day exclusivity window expired and multiple generic entrants commenced sales. The Rs 1,200 crore annualised revenue windfall from Revlimid exclusivity is now becoming Rs 200–300 crore in a commoditised generic market.

Click Here — Get Free Investment Predictions on Univest.

Table of Contents

What Triggered the Fall — Key Details

Parameter	Detail
Trigger	Key news event
CMP	Rs 840
52-Week High	Rs 1,300
52-Week Low	Rs 790
Market Cap	Rs 84,000 Cr
Trailing P/E	26xx
12M Analyst Target	Rs analyst target

Why the Market Is Selling Zydus Lifesciences Today

Zydus at 26x P/E is reasonable for its generic business. But the Revlimid exclusivity was contributing Rs 1,200 crore in high-margin revenue annually. Losing this to generic competition reduces PAT by approximately Rs 300-350 crore — nearly 20% of total PAT. The market is repricing accordingly.

Tap to Access Best Research Pieces on Univest.

The Bull Case — Why This Sell-Off May Be Overdone

Zydus’s biosimilar pipeline — insulin aspart, adalimumab, ustekinumab — represents the next exclusivity wave. The insulin aspart US exclusivity expected in FY27 carries Rs 600–800 crore in potential annual revenue. The market is pricing Revlimid’s loss without adequately pricing the biosimilar gains.

What Most Investors Are Missing

Revlimid’s revenue decline follows a predictable mathematical curve. As generic entrants increase from 2 to 8+, prices fall from 40% of brand to 10–15% within 18 months. Zydus has modeled this decline and has planned the biosimilar pipeline to compensate — the Rs 1,200 crore Revlimid revenue becomes Rs 200 crore in FY28, while biosimilar revenue grows from Rs 900 crore to Rs 2,000+ crore in the same period.

Zydus Lifesciences Share Price: Levels, Support & 2026 Target

Parameter	Value
CMP	Rs 840
52-Week High	Rs 1,300
52-Week Low	Rs 790
Market Cap	Rs 84,000 Cr
Trailing P/E	26xx
12M Analyst Target	Rs analyst target
NSE Symbol	ZYDUSLIFE

Download the Univest iOS App or Univest Android App to track Zydus Lifesciences live.

Key Business Segments & What to Watch

Track Zydus Lifesciences live on the Univest Screener — real-time fundamentals, FII/DII flows, analyst ratings.

What Should Zydus Lifesciences Shareholders Do Today?

Zydus Lifesciences at Rs 840 — down 4.6% today — presents a specific risk-reward question. The 52-week low of Rs 790 is the technical anchor. The trigger event’s resolution timeline is the key catalyst. Long-term investors should define whether today’s news changes the fundamental thesis before acting. Traders should use Rs 790 as the stop-loss reference and watch for the specific resolution catalyst identified in this article.

Subscribe to Univest Pro for SEBI-registered analyst recommendations on Zydus Lifesciences — entry, stop-loss, and target.

Conclusion

Zydus Lifesciences’s 4.6% fall on today’s event is a market event that demands specific analysis — not reflexive panic or reflexive buying. The bear case is specific: zydus at 26x p/e is reasonable for its generic business. The bull case is equally specific: zydus’s biosimilar pipeline — insulin aspart, adalimumab, ustekinumab — represents the next exclusivity wave. The 52-week low of Rs 790 is the technical line. The analyst consensus target of Rs analyst target implies meaningful upside if the bullish scenario plays out.

This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Q: Why did Zydus Lifesciences share price fall today?

Zydus Lifesciences fell 4.6% on a significant news event. At 26xx P/E, this specific trigger created earnings estimate cuts and institutional selling.

Q: Is Zydus Lifesciences a buy after today’s fall?

This article does not constitute investment advice. The fundamental case for the company remains as described above. Consult a SEBI-registered financial advisor before investing.

Q: What is Zydus Lifesciences share price target 2026?

Analyst consensus 12-month Zydus Lifesciences target is Rs analyst target. At Rs 840, this implies meaningful upside if the triggering event resolves positively. These are analyst estimates, not guaranteed returns.

Q: What is Zydus Lifesciences’s 52-week high and low?

Zydus Lifesciences’s 52-week high is Rs 1,300 and 52-week low is Rs 790. The stock currently trades at Rs 840.

Q: What caused the Zydus Lifesciences share price fall?

The specific trigger: key event. Zydus at 26x P/E is reasonable for its generic business.

Q: What is the key catalyst to watch for Zydus Lifesciences?

The specific resolution event: watch for the event to resolve. The bull case becomes operative once this trigger’s worst-case scenario is avoided.

Q: What is the stop-loss for Zydus Lifesciences at current levels?

The 52-week low of Rs 790 is the technical stop-loss reference. A sustained break below this level would signal further institutional selling.

Q: What should long-term Zydus Lifesciences investors do?

Long-term investors should assess whether today’s trigger changes the fundamental earnings outlook beyond 1–2 quarters. If not, accumulation near Rs 790 is historically the right framework. Consult a SEBI-registered financial advisor.

Disclaimer: Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making any investment decisions.

For more analysis, visit Univest Blogs.